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Abstract
As a part of our continuing study of colchicinoids as therapeutically useful antitumor drugs,
thiocolchicine derivatives, including their phosphate and other water soluble salts, were
synthesized and evaluated for inhibition of tubulin polymerization and for in vitro cytotoxicity.
Three compounds, 7, 10, and 11, showed potent inhibition of tubulin assembly (IC50 = 0.88 – 1.1
μM). In addition, compound 7, a water soluble succinic acid salt of N-deacetylthiocolchicine (4),
showed potent cytotoxicity against a panel of tumor cell lines, suggesting it might be a potential
lead to be developed as a therapeutic antitumor agent. Compound 8, a water soluble succinic acid
salt of N,N-dimethyl-N-deacetylthiocolchicine (5), showed selective activities against HCT-8 and
SK-BR-3 cells. N,N-Diethyl-N-deacetylthiocolchicine (6) seemed not to be a substrate for the P-gp
efflux pump, based on the similar ED50 values obtained against P-gp over-expressing KBvin
(0.0146 μg/mL) cells and the parent KB (0.0200 μg/mL) cell line.
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Colchicine (1), an alkaloid isolated from Colchicum autumnale and Gloriosa superba, is
known to possess notable anti-inflammatory, anti-mitotic, and anti-fibrotic effects.2
Although colchicine has significant in vitro antitumor effects, its medicinal uses, as well as
use of its derivatives, has been limited because of high toxicity, low bioavailability, and poor
water solubility.3 Thiocolchicine (2), originally derived from colchicine by semi-synthesis,
possesses comparable or greater biological activity than colchicine (1) and has been studied
for many years.2 Although 2 is structurally more stable than 1, its substantial toxicity and
poor water solubility limit interest in it as a drug candidate. Many efforts have been made to
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© 2010 Elsevier Ltd. All rights reserved.
*Corresponding author. Tel.: 919-962-0066, fax: 919-966-3893, khlee@unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 July 15.
Published in final edited form as:













develop thiocolchicine analogs with the goal of reducing toxicity and increasing
watersolubility.3, 4 2-Demethylthiocolchicine (3) was found to be slightly less active but
also less toxic than 2 and 1.5 N-Deacetylthiocolchicine (4) was previously synthesized and
was similar to 2 in its inhibitory effect on tubulin assembly.6 These findings suggested that
further modifications could lead to more active compounds with reduced toxicity or greater
water solubility and thus have greater potential as drug candidates.
The preparation of di-alkyl-substituted amines of N-deacetylthiocolchicine (4) and related
pharmaceutically and clinically accepted salts and phosphate derivatives has not been
described. In this paper, we report such modifications of thiocolchicine and its derivatives at
the amino group at C7 and at the hydroxy group at C2 of 3 and 4.
Treatment of 46 with formaldehyde and acetaldehyde in the presence of NaBH3CN under
acidic conditions yielded N,N-dimethyl- (5) and N,N-diethyl-N-deacetylthiocolchicine (6) in
80% and 82% yields, respectively, without obtaining N-mono-alkyl-substituted compounds
(Scheme 1). Amines 4–6 were converted to corresponding succinic acid salts 7–9 in
quantitative yields.
A series of N-mono-alkylated analogs of 4 was synthesized through ready addition and
removal of the o-nitrobenzenesulfonamide (o-Ns) group, which is widely tolerant of basic
and acidic conditions (Scheme 2). According to Fukuyama’s protocol,7 4 was converted to
N-[o-Ns]-N-deacetylthiocolchicine (10) with o-NsCl in the presence of 2,6-lutidine in
CH2Cl2, followed by alkylation with RI (R = Me, Et or Pr) in the presence of K2CO3 in
MeCN to afford 11, 12 and 13 in 72%, 97% and 53% overall yields, respectively. Treatment
of 11 with BBr3 in CH2Cl2 at −78°C succeeded in the regioselective demethylation to afford
14 in 75% yield, while the reported method8 by heating with H2SO4 gave a lower yield of
the desired compound. The o-Ns group was removed from 14 with thioglycolic acid and
Et3N in CH2Cl2 to obtain the secondary amine 15 in 59% yield. Compound 16, a phosphate
of 15, was synthesized by using POCl3 in MeCN and purified with reverse phase column
chromatography (MeOH–H2O). Treatment of 15 with succinic acid in acetone gave 17. The
water solubility at room temperature of analogs 7–9, 16, and 17 were 180 mg/mL, 103 mg/
mL, 107 mg/mL, 15 mg/mL and 95 mg/mL, respectively.
All newly synthesized compounds were evaluated for effects on tubulin assembly and in
vitro antitumor activities against several tumor cell lines. Studies were also performed with
colchicine (1), thiocolchicine (2), and N-deacetylthiocolchicine (4). The cell line panel
included KB (human epidermoid carcinoma of the nasopharynx), HCT-8 (human ileocecal
carcinoma), A549 (human lung adenocarcinoma), DU145 (human prostate carcinoma), SK-
BR-3 (human breast cancer) and KBvin (vincristine-resistant line derived from the KB cell)
cells. In addition, the most active inhibitors of tubulin assembly were also evaluated as
inhibitors of the binding of [3H]colchicine to tubulin. The tubulin data are summarized in
Table 1. Relative to the activity shown by 2 and 3, N,N-dimethyl- (5) and N,N-diethyl-N-
deacetylthiocolchicine (6), derived from 4 by alkylation, exhibited reduced activity as
inhibitors of both tubulin assembly and colchicine binding Compounds 7, 8, and 9 are three
succinic acid salts of 4, 5, and 6. Compound 7, derived from N-deacetylthiocolchicine (4),
had activity comparable with that of its parent compound 4, while compounds 8 and 9, salts
of 5 and 6, were somewhat less potent than their parent compounds. N-o-Ns substituted
compounds 10 and 11, with no other N-alkyl (10) or a methyl substitutuent (11) in addition
to the o-Ns group, also displayed potent anti-tubulin activities. However, replacing the
methyl group with an ethyl (12) or propyl (13) moiety led to reduced or lost activity relative
to compound 11 in the tubulin assays. This suggests that the size of alkyl groups at the C7–
amino position of N-deacetylthiocolchicines may play a role in the interaction of these
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compounds with the binding site of the target protein, while the o-Ns group may not
significantly affect antitubulin activity.
2-Demethylthiocolchicine (3) was previously reported as an active inhibitor of tubulin
assembly and colchicine binding. 3 However, in our recent study, a series of 2-demethyl-N-
deacetylthiocolchicine derivatives (14–17) showed reduced activity against tubulin
assembly. Compared with the parent compound 11, compound 14, the 2-demethyl derivative
of 11, was about four times less active against tubulin assembly (IC50 = 3.6 μM) and half as
potent in inhibition of colchicine binding (20% inhibition of colchicine binding). Compound
15, the N-de-o-Ns analog of compound 14, showed remarkably reduced activity as an
antitubulin agent, since it was essentially inactive as an inhibitor of tubulin assembly (IC50 >
40 μM). These findings suggest that a trimethoxyphenyl moiety with its lipophilic molecular
feature may be required for N-deacetylthiocolchicines to fit into a hydrophobic pocket in the
binding site. The acetamido group at C7 of compound 3 may play a role in maintaining the
drug molecule in a suitable conformation to interact with the target protein. Although the
hydroxy group at C2 of compound 16 was masked with a phosphoryl moiety, the highly
polar and H-bonding properties of the phosphate moiety may prevent the molecule from
interacting optimally with the colchicinebinding domain and thereby eliminating its anti-
tubulin activity (IC50 > 40 μM).
In vitro antitumor activities of the newly synthesized compounds were evaluated, and the
results are summarized in Table 2. Consistent with the tubulin data discussed above, 5 and 6,
N-deacetylthiocolchicine derivatives with N,N-di-alkyl substituents at C7, were on average
ten times more active than the non-alkyl substituted compound 4. The N,N-diethyl
compound 6 generally had antiproliferative activity similar to that of the N,N-dimethyl
compound 5 and colchicine (1). Compound 6 was the only highly active agent tested that
was equally active against the vincristine resistant, MDR nasopharyngeal cancer cell line
(KBvin) as the parental non-MDR KB cell line. This result suggests that the size of N-alkyl
substituent at C7 may affect recognition of a colchicinoid by P-glycoprotein and/or the
mechanism of action of 6 may be other than inhibition of tubulin activity. Although, in
general, the succinic acid salts, 7–9, showed decreased activities relative to their parent
compounds 4–6 N,N-dimethyl compound 8 was selectively more potent against HCT-8
(ED50 = 0.0220 μg/mL) and SK-BR-3 (ED50 = 0.0129 μg/mL) than its parent compound 5,
and 8 was 10-fold more cytotoxic against other tested cell lines. The cytotoxicity of N-o-Ns-
N-deacetylthiocolchicine derivatives, 10–13, revealed the same tendency as described
above. In summary, the smaller alkyl substituents on the amino group at the C7–position
tended to have stronger activities against all cell lines (10, R = H > 11, R = Me > 12, R = Et
> 13, R = Pr). N-non-alkyl-substituted N-[o-Ns] compound 10 showed the highest activity
among 10–13 against all tested cell lines (ED50 = 0.0100–0.0270 μg/mL). Although 2-
demethylthiocolchicine (3) showed similar activity to thiocolchicine (2) (ED50 = 0.01 μg/
mL against A549, 0.01 μg/mL against KB),3 the cytotoxic potency decreased for the 2-
demethyl-N-[o-Ns]-N-deacethylthiocolchicine series (e.g., 11 vs. 14), as occurred in the
tubulin assay. Differing from the tubulin assay results, compound 15, derived from 14 by
removal of the o-Ns protection group, did not show significant loss in inhibition of tumor
cell growth. In addition, the inhibitory activity toward DU145 and SK-BR-3 cells slightly
increased. Compound 16, a phosphate of 15, showed two-three times more potent
cytotoxicity than 15 against A549, DU145, SK-BR-3, and KB cell growth, suggesting that
the phosphate group may increase selectivity to the target tumor cells. Notably, the new
compounds, N,N-dialkyl-N-deacetylthiocolchicines, 5 and 6, as well as the succinates, 7–9,
showed comparable or better cytotoxicity against P-gp over-expressing KBvin cells than
colchicine.
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In summary, modifications of the amino group at C7 and the methoxy group at C2 of N-
deacetylthiocolchicine (4) were achieved. Two N,N-di-alkyl-N-deacetylthiocolchicine
deerivatives, 5 and 6, corresponding succinates 7–9, N-[o-Ns]-N-deacetylthiocolchicines 10–
13, and 2-demethyl-N-methyl-N-deacetylthiocolchicines 14 and 15, salt 17, and C2–
phosphate 16 were generated. We analyzed this series of compounds for their anti-tubulin
activity and in vitro cytotoxicity. Although none of the newly synthesized compounds
showed more potent activity than their parent compound 4 or thiocolchicine (2), the succinic
acid salts, especially compound 7, have potential as promising antitumor agents, because of
both their excellent antiproliferative activity and their superior water solubility. The size of
the N-substituted alkyl groups played a role in inhibition of tubulin assembly and colchicine
binding and in vitro cytotoxicity. Generally, the larger alkyl substituents showed reduced
activity against both tubulin and tumor cell growth. N,N-Diethyl analog 6, however, showed
more potent cytotoxicity than its N,N-dimethyl counterpart, which differed somewhat from
the tubulin results. This result may indicate an additional mechanism of action for 6 versus
5. In addition, compound 6 also showed higher potency against the KBvin cell line relative
to the parental KB line. Thus, compound 6 may merit further investigation to understand its
apparent resistance to the P-gp efflux pump. Finally, the succinic acid salt of N,N-dimethyl-
N-deacetylthiocolchicine, compound 8, showed selective activities against HCT-8 and SK-
BR-3 cells.
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Reagents and conditions; a) RCHO (D=H or Me), NaBH3CN, HOAc,CH2Cl2, 5; 80%
(R’=H), 6; 82% (R’=Me); b) succinic acid, acetone, 7, 8, 9; quant.
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Reagents and conditions; a) o-NsCl, 2,6-lutidine, CH2Cl2; b) Rl (R=Me, Et or Pr), K2CO3,
MeCN 11; 85% 12; 97% 13; 53%; c) BBr3, CH2Cl2, −78 °C, 75%; d) thioglycolic acid,
Et3N, 59%; e) POCl3, Et3N, MeCN, 0 °C to rt; then H2O, pyridine,43%; f) succinic acid,
acetone, quant.
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Table 1
Inhibition of tubulin assembly of 2–17
Compound Inhibition of tubulin assemblyIC50 (μM) ± SD
Inhibition of colchicine binding
% Inhibition ± SD
5 μM 50 μM
2 0.77 ± 0.2 74 ± 2 NDa
4 0.91 ± 0.05 63 ± 1 ND
5 2.5 ± 0.3 42 ± 4 88 ± 0.6
6 5.4 ± 0.2 31 ± 3 84 ± 3
7 0.88 ± 0.03 64 ± 2 ND a
8 3.6 ± 0.04 27 ± 4 85 ± 0.1
9 16 ± 1 17 ± 6 65 ± 1
10 1.1 ± 0.06 58 ± 2 ND
11 0.92 ± 0.03 43 ± 3 60 ± 2
12 4.2 ± 0.7 22 ± 5 26 ± 5
13 > 40 ND a ND
14 3.6 ± 0.2 20 ± 7 34 ± 6
15 > 40 ND ND
16 > 40 ND ND
17 23 ± 1 ND ND




Combretastin A-4: positive control











































































































































































































































































































































































































































































































































































































































Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 July 15.
